Imaging biomarkers in alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 1180, Issue , 2009, Pages 20-27

  Ryan, Natalie S ^a   Fox, Nick C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease (AD); Magnetic resonance imaging (MRI); Mild cognitive impairment (MCI); Positron emission tomography (PET)

Indexed keywords

BIOLOGICAL MARKER; CARBON 11; FLUORODEOXYGLUCOSE;

ALZHEIMER DISEASE; BRAIN FUNCTION; BRAIN PERFUSION; BRAIN REGION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; CLINICAL RESEARCH; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; DEMYELINATION; DISEASE COURSE; ELECTROENCEPHALOGRAM; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; INFLAMMATORY DISEASE; MENINGOENCEPHALITIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 70449411526     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05062.x     Document Type: Conference Paper

References (29)

1. Zola-Morgan, S. 1995. Localization of brain function: the legacy of Franz Joseph Gall (1758-1828). Annu. Rev. Neurosci. 18: 359-383.
2. Knopman, D.S. et al. 2001. Practice parameter: diagnosis of dementia (an evidence-based review). Report of theQuality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1143-1153.
3. Price, J.L. & J.C. Morris. 1999. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45: 358-368.
4. Waldemar, G. et al. 2007. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur. J. Neurol. 14: e1-e26.
5. Hodges, J.R. & K. Patterson. 2007. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol. 6: 1004-1014.
6. Schroter, A. et al. 2000. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch. Neurol. 57: 1751-1757.
7. Manners, D.N. et al. 2009. Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease. Neurology 72: 1425-1431.
8. Schmidt, R. 1992. Comparison of magnetic resonance imaging in Alzheimer's disease, vascular dementia and normal aging. Eur. Neurol. 32: 164-169.
9. Jack, C.R., Jr. et al. 2002. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 58: 750-757.
10. DeCarli, C. et al. 2007. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch. Neurol. 64: 108-115.
11. Scheltens, P. et al. 1992. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J. Neurol. Neurosurg. Psychiatry 55: 967-972.
12. de Leon, M.J. et al. 1997. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol. Aging 18: 1-11.
13. Duara, R. et al. 2008. Medial temporal lobe atrophy onMRIscans and the diagnosis of Alzheimer disease. Neurology 71: 1986-1992.
14. Likeman, M. et al. 2005. Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias. Arch. Neurol. 62: 1410-1415.
15. Dubois, B. et al. 2007. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSADRDA criteria. Lancet Neurol. 6: 734-746.
16. Silverman, D.H. et al. 2001. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286: 2120-2127.
17. Jagust, W., B. Reed, D. Mungas, et al. 2007. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69: 871-877.
18. Fox, N.C. & J. Kennedy. 2009. Structural imaging markers for therapeutic trials in Alzheimer's disease. J. Nutr. Health Aging 13: 350-352.
19. Devanand, D.P. et al. 2007. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 68: 828-836.
20. Forsberg, A. et al. 2008. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29: 1456-1465.
21. Rowe, C.C. et al. 2007. Imaging amyloid burden in aging and dementia. Neurology 68: 1718-1725.
22. Gilman, S. et al. 2005. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562.
23. Schuff, N. et al. 2009. MRI of hippocampal volume loss in early Alzheimer's disease in relation to Apo E genotype and biomarkers. Brain 132: 1067-1077.
24. Fox, N.C. et al. 2005. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64: 1563-1572.
25. Chan, D. et al. 2003. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 362: 1121-1122.
26. Vellas, B. et al. 2009. Long-term follow-up of patients immunizedwithAN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6: 144-151.
27. Frisoni, G.B. & A. Delacourte. 2009. Neuroimaging outcomes in clinical trials in Alzheimer's disease. J. Nutr. Health Aging 13: 209-212.
28. Engler,H. et al. 2006. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129: 2856-2866.
29. Selkoe, D.J. 2008. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192: 106-113.